Twin Peaks Wealth Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$185	–	1415
2026 Q1	$185	Buy	+2	New	+$188	﹤0.01%	2181

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Twin Peaks Wealth Advisors's MIRM Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Mirum Pharmaceuticals (MIRM) in Q2 2026, closing a stake of 2 shares — an estimated $185 sold.

Twin Peaks Wealth Advisors first reported a position in MIRM in Q1 2026 and held it in 1 quarter. The position peaked at $185 in Q1 2026. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Twin Peaks Wealth Advisors reported no remaining Mirum Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Twin Peaks Wealth Advisors sold 2 Mirum Pharmaceuticals shares in Q2 2026, an estimated $185.
Twin Peaks Wealth Advisors first reported a position in Mirum Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Twin Peaks Wealth Advisors's Mirum Pharmaceuticals position peaked at $185 in Q1 2026.
327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.